JP2022191383A5 - - Google Patents

Download PDF

Info

Publication number
JP2022191383A5
JP2022191383A5 JP2022164041A JP2022164041A JP2022191383A5 JP 2022191383 A5 JP2022191383 A5 JP 2022191383A5 JP 2022164041 A JP2022164041 A JP 2022164041A JP 2022164041 A JP2022164041 A JP 2022164041A JP 2022191383 A5 JP2022191383 A5 JP 2022191383A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
seq
nos
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022164041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022191383A (ja
Filing date
Publication date
Priority claimed from JP2019549574A external-priority patent/JP7159185B2/ja
Application filed filed Critical
Publication of JP2022191383A publication Critical patent/JP2022191383A/ja
Publication of JP2022191383A5 publication Critical patent/JP2022191383A5/ja
Priority to JP2024055230A priority Critical patent/JP2024088689A/ja
Withdrawn legal-status Critical Current

Links

JP2022164041A 2017-03-16 2022-10-12 抗phf-タウ抗体及びその使用 Withdrawn JP2022191383A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024055230A JP2024088689A (ja) 2017-03-16 2024-03-29 抗phf-タウ抗体及びその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762472214P 2017-03-16 2017-03-16
US62/472,214 2017-03-16
JP2019549574A JP7159185B2 (ja) 2017-03-16 2018-03-16 抗phf-タウ抗体及びその使用
PCT/US2018/022782 WO2018170351A1 (en) 2017-03-16 2018-03-16 Anti-phf-tau antibodies and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019549574A Division JP7159185B2 (ja) 2017-03-16 2018-03-16 抗phf-タウ抗体及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024055230A Division JP2024088689A (ja) 2017-03-16 2024-03-29 抗phf-タウ抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2022191383A JP2022191383A (ja) 2022-12-27
JP2022191383A5 true JP2022191383A5 (enExample) 2023-06-01

Family

ID=63521020

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019549574A Active JP7159185B2 (ja) 2017-03-16 2018-03-16 抗phf-タウ抗体及びその使用
JP2022164041A Withdrawn JP2022191383A (ja) 2017-03-16 2022-10-12 抗phf-タウ抗体及びその使用
JP2024055230A Withdrawn JP2024088689A (ja) 2017-03-16 2024-03-29 抗phf-タウ抗体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019549574A Active JP7159185B2 (ja) 2017-03-16 2018-03-16 抗phf-タウ抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024055230A Withdrawn JP2024088689A (ja) 2017-03-16 2024-03-29 抗phf-タウ抗体及びその使用

Country Status (22)

Country Link
US (3) US10766953B2 (enExample)
EP (1) EP3596119A4 (enExample)
JP (3) JP7159185B2 (enExample)
KR (2) KR102695287B1 (enExample)
CN (2) CN117209599A (enExample)
AR (1) AR111288A1 (enExample)
AU (1) AU2018234709B2 (enExample)
CA (1) CA3055598A1 (enExample)
CL (1) CL2019002566A1 (enExample)
EA (1) EA201992038A1 (enExample)
IL (2) IL310464A (enExample)
JO (1) JOP20180021A1 (enExample)
MA (1) MA47789A (enExample)
MX (2) MX2019010922A (enExample)
MY (1) MY205672A (enExample)
PH (1) PH12019501973A1 (enExample)
SG (1) SG11201907754RA (enExample)
TW (1) TWI771389B (enExample)
UA (1) UA128385C2 (enExample)
UY (2) UY37635A (enExample)
WO (1) WO2018170351A1 (enExample)
ZA (2) ZA202101318B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY178142A (en) * 2011-12-20 2020-10-05 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
SG11201808434WA (en) 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
WO2019077500A1 (en) 2017-10-16 2019-04-25 Eisai R&D Management Co., Ltd. ANTI-WATER ANTIBODIES AND USES THEREOF
JP7362636B2 (ja) 2018-03-05 2023-10-17 ヤンセン ファーマシューティカ エヌ.ベー. 抗phf-タウ抗体及びその使用
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
EP3977135A1 (en) * 2019-05-31 2022-04-06 Eli Lilly And Company Compounds and methods targeting human tau
WO2021024209A1 (en) * 2019-08-06 2021-02-11 Aprinoia Therapeutics Inc. Antibodies that bind to pathological tau species and uses thereof
IL297231A (en) * 2020-04-08 2022-12-01 Janssen Biotech Inc Anti-phf-tau antibodies and uses thereof
WO2022013286A1 (en) * 2020-07-14 2022-01-20 Janssen Pharmaceutica Nv Blood-based assay for detecting tauopathy or amyloidogenic disease
WO2022090169A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Method of safe administration of anti-tau antibody
WO2022090158A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
KR20230147034A (ko) * 2021-02-19 2023-10-20 에자이 알앤드디 매니지먼트 가부시키가이샤 항-pt217 타우 항체
AU2022242135A1 (en) 2021-03-26 2023-11-09 Janssen Biotech, Inc. Anti-tau antibodies and uses thereof
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
AU2023342086A1 (en) 2022-09-15 2025-03-13 Voyager Therapeutics, Inc. Tau binding compounds
CN116948023B (zh) * 2023-09-14 2024-02-09 北京凯祥弘康生物科技有限公司 Tau蛋白抗体及其应用
CN116948024B (zh) * 2023-09-14 2024-02-06 北京凯祥弘康生物科技有限公司 抗Tau蛋白的捕获抗体
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP0610330B1 (en) 1991-10-25 1997-06-18 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau
ES2270421T3 (es) 1993-12-21 2007-04-01 Innogenetics N.V. Anticuerpos monoclonales especificos para phf-tau, hibridomas que secretan los mismos, reconocimiento de antigeno por estos anticuerpos y sus aplicaciones.
JPH10506381A (ja) 1994-07-29 1998-06-23 イノジェネティックス・ナムローゼ・フェンノートシャップ 特定のサブクラスまたは形態のホスホリレーションされたtauのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CN1780855B (zh) * 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
AU2005214988A1 (en) 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
KR20140033236A (ko) 2006-08-04 2014-03-17 노바르티스 아게 Ephb3-특이적 항체 및 이의 용도
JP2010235447A (ja) 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US8748386B2 (en) 2009-06-10 2014-06-10 New York University Immunological targeting of pathological Tau proteins
US8912355B2 (en) 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク,インコーポレーテツド 抗体を親和性成熟する方法
CN105968206B (zh) 2010-04-09 2020-01-17 Aveo制药公司 抗erbb3抗体
HUE027649T2 (en) 2010-10-07 2016-10-28 Ac Immune Sa Antibodies recognising phospho-tau
EA031698B1 (ru) 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела
MY178142A (en) * 2011-12-20 2020-10-05 Janssen Biotech Inc Anti-phf-tau antibodies and their uses

Similar Documents

Publication Publication Date Title
JP2022191383A5 (enExample)
JP2024109678A5 (enExample)
JP2022106952A5 (enExample)
JP2025065427A5 (enExample)
JP2024038003A5 (enExample)
JP2023121798A5 (enExample)
JP2022177090A5 (enExample)
JP2023093753A5 (enExample)
JP2023116770A5 (enExample)
JP2018536393A5 (enExample)
JPWO2019173291A5 (enExample)
RU2012112829A (ru) Анти-gitr-антитела
JP2020537520A5 (enExample)
AR123083A1 (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
JP2020511946A5 (enExample)
JP2024024114A5 (enExample)
JP2020505927A5 (enExample)
JP2020522280A5 (enExample)
JP2025016538A5 (enExample)
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
JP2025067915A5 (enExample)
JP2020515277A5 (enExample)
JPWO2019209995A5 (enExample)
JP2021512652A5 (enExample)
JP2025087764A5 (enExample)